Michael McClung, MD, FACP, FACE is the founding director of the Oregon Osteoporosis Center. He graduated from Rice University in Houston and from the University of Texas Southwestern Medical School in Dallas. After his training in Internal Medicine at Parkland Hospital in Dallas, he completed a fellowship in Endocrinology at the National Institute of Health in Bethesda, Maryland. He was actively involved in the training of young physicians while on the faculty at the Oregon Health Sciences University and in the Department of Medical Education at Providence Portland Medical Center.

Dr. McClung conducts research in osteoporosis, particularly the study of therapeutic agents and tests for diagnosis and monitoring. He is the Associate Clinical Editor of BoneKey and serves on editorial board of several other journals. He has been on the US Food and Drug Administration (FDA) Advisory Committee for Endocrine and Metabolic Drugs and the WHO Fracture Risk Assessment Task Force that led to the development of the FRAX tool. He is active in numerous professional organizations and has published many scientific articles and book chapters.